Valvular & structural heart disease
Transcatheter Mitral Valve Replacement With Atrial Fixation for Treatment of Atrial Functional Mitral Regurgitation
Authors' conclusion
The AltaValve system shows promising early procedural and clinical results for the unique anatomy of patients with atrial functional mitral regurgitation. Long-term clinical studies to demonstrate the benefit of this system are warranted.
Study context
- Population
- Patients with severe, symptomatic atrial functional mitral regurgitation treated with transcatheter mitral valve replacement using the AltaValve systempatients treated · transseptal delivery 11 · transapical approach 3
- Participants
- 14 patients
- Outcome
- Technical success and mitral regurgitation reduction from severe to none/trace
Methodological detailscompassionate use exemption
- Compassionate use exemption
Main finding
As reported in the abstract
- Achieved in all cases
Further findings
Left ventricular outflow tract obstruction
- No cases
All-cause mortality · 30 days
- All-cause mortality
- 14% (2/14)
Class III/IV New York Heart Association status · 30 days
- Baseline
- 79%
- 30 days
- 0%
Mitral regurgitation severity · 30 days
- Trace/none
- 90.9% (10/11)
- Mild
- 9.1% (1/11)
- 11 of 12 surviving patients had an available echocardiogram
Original publication
Transcatheter Mitral Valve Replacement With Atrial Fixation for Treatment of Atrial Functional Mitral Regurgitation. Circ Cardiovasc Interv. Published 20 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →